F. Vandenberghe

Discipline

Psychologie (8) Sociologie (1) Histoire, Philosophie et Sociologie des sciences (1)

Discipline

Sociologie (1)

Type de document

Articles (31) Recensions (9)

Type de document

Textes imprimés (1)

Co-auteur

Date

Date

Source

Source

Mot-clé

Patients (20) Treatment (18) Patients (18) Human beings (16) risque (14) Risk (14) Population (12) Population (12) Psychotropic drugs (11) Obesity (11) cohorte (11) poids (10) association (10) âge (10) Weight gain (10) Social groups (10) Psychotherapy patients (10) Psychiatry (10) Age (10) Body mass index (10) Weight (10) Age (10) adulte (9) Months (9) adulte (9) thérapie (8) Therapeutics (8) Older people (8) santé (7) effet (7)

Mot-clé

Paris (1) Sociological aspects (1) Sociología (1) Sociologie (1) Sociologie (1) Paris (1)

Documents écrit par F. Vandenberghe (31) | parle de F. Vandenberghe (1)

Prescription d’antipsychotiques chez les adultes : à quoi faut-il être attentif ? [Antipsychotic prescribing in adults : what to watch out for ?]
C. Grandjean et al. (20 sept. 2023)
Identification of four novel loci associated with psychotropic drug-induced weight gain in a Swiss psychiatric longitudinal study: A GWAS analysis.
J. Sjaarda et al.
The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samples.
B.I. Perry et al.
Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohort.
N. Laaboub et al. (17 mai 2022)
Olanzapine-associated dose-dependent alterations for weight and metabolic parameters in a prospective cohort.
G. Schoretsanitis et al.
Le liraglutide a-t-il sa place en psychiatrie ? [Does liraglutide have a place in psychiatry ?]
J. Frantz et al. (23 mars 2022)
Gabapentinoïdes : mésusages et addictions [Gabapentinoids : misuses and addictions]
C. Grandjean et al. (15 déc. 2021)
Recommandations de prise en charge des mésusages et addictions aux benzodiazepines [Recommendations for management of misuses and addictions to benzodiazepines]
C. Grandjean et al. (13 oct. 2021)
Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants.
C.B. Eap et al.
Benzodiazépines, addiction et autorisation cantonale : cadre juridique et implications cliniques [Benzodiazepines, addiction and cantonal authorization : legal framework and clinical implications.]
V. Junod et al. (9 juin 2021)
Traitement de l’insomnie, par quoi commencer ? [Treatment of insomnia, with what to start ?]
C. Grandjean et al. (5 mai 2021)
Bioavailability of Vortioxetine After a Roux-en-Y Gastric Bypass.
F. Vandenberghe et al.
Psychiatrie [Psychiatry]
Y. Khazaal et al. (13 janv. 2021)
Associations Between High Plasma Methylxanthine Levels, Sleep Disorders and Polygenic Risk Scores of Caffeine Consumption or Sleep Duration in a Swiss Psychiatric Cohort.
N. Laaboub et al. (2021)
Agitation aiguë chez l’adulte : proposition d’un algorithme de traitement psychopharmacologique [Rapid tranquilisation in adults : algorithm proposed for psychopharmacological treatment]
S. Crettol Wavre et al. (23 sept. 2020)
Psychological trauma occurring during adolescence is associated with an increased risk of greater waist circumference in Early Psychosis patients treated with psychotropic medication.
L. Alameda et al. (2020)
Lipid Disturbances in Adolescents Treated With Second-Generation Antipsychotics: Clinical Determinants of Plasma Lipid Worsening and New-Onset Hypercholesterolemia.
A. Delacrétaz et al. (9 avr. 2019)
Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients.
L. Quteineh et al.
Second-Generation Antipsychotics in Adolescent Psychiatric Patients: Metabolic Effects and Impact of an Early Weight Change to Predict Longer Term Weight Gain.
F. Vandenberghe et al.
Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia.
A. Delacrétaz et al. (2018)
Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs.
A. Delacrétaz et al.
Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs.
A. Delacrétaz et al. (10 sept. 2017)
Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers.
F. Vandenberghe et al.
Association of CRTC1 polymorphisms with obesity markers in subjects from the general population with lifetime depression.
L. Quteineh et al. (1 juil. 2016)
Association of genetic risk scores with body mass index in Swiss psychiatric cohorts.
N. Saigi-Morgui et al. (2016)

next
F. Vandenberghe, La sociologie de Georg Simmel, Paris, La Découverte, coll. « Repères », 2001
Jean-François Landry (2002)